

科技部補助專題研究計畫成果報告 期末報告

研究長春鹼化療藥物對愛寧達之抗藥性肺癌細胞所引起的死亡 機制

計畫類別：個別型計畫
計畫編號：MOST 104-2320-B-040-003-
執行期間：104年08月01日至105年07月31日
執行單位：中山醫學大學醫學研究所

計畫主持人：許國堂

計畫參與人員：碩士級-專任助理人員：丘翎燕
碩士班研究生-兼任助理人員：許倍瑄

中華民國 105 年 08 月 31 日

中文摘要：目前認為是因為胸苷酸合成酶(TS)蛋白質高量造成肺癌對愛寧達產生抗藥性，可是對如何解決愛寧達產生之抗藥性並無相關的研究。因此尋找有效的第二線化療用藥來對付具有愛寧達抗藥性之肺癌就顯得非常需要。在癌組織中高表達的胸苷酸合成酶被認為會對愛寧達的化療藥在治療晚期的非小細胞肺癌中的非鱗狀上皮癌產生抗藥性。為了深入研究愛寧達產生的抗藥性機制和可能因此會對肺癌治療的預後有重要的影響，我們使用兩株抗愛寧達藥物細胞株 A549/A400 (TP53 野生型) 和 CL1/A200 (TP53-突變型) 來做為此次研究的材料。

我們首先證明了在這兩株抗愛寧達藥物細胞株中的胸苷酸合成酶 (TS) 都呈現高表達，如果使用干擾胸苷酸合成酶的 shRNA 來抑制胸苷酸合成酶的表達會讓抗愛寧達藥物細胞株對愛寧達產生敏感性。我們也在細胞和動物的模式下證明得到愛寧達的抗藥性會增強上皮-間質轉化所造成的轉移能力 (EMT)，這個轉移能力是透過 ZEB1 這個 E-cadherin 基因轉錄抑制因子來抑制上皮鈣粘蛋白 (E-cadherin) 和增加纖維結合蛋白 (fibronectin) 的表達。當 ERK1/2 蛋白激酶的磷酸化被其抑制劑 (U0126) 或是小干擾 RNA 所降低，這兩株抗愛寧達藥物細胞的遷移和侵襲的能力就顯著的減少。

我們以前曾經證明愛寧達會利用 ERK 的訊息路徑來引起肺癌細胞的凋亡，因此我們認為當經由 ERK 的訊息路徑無法引起肺癌細胞的凋亡而變成抗愛寧達藥物的肺癌細胞後，這個 ERK 的訊息路徑反而會增加肺癌細胞的轉移能力。同時，我們進一步使用另一類的化療藥敏畢瘤 (vinblastine) 以及敏克瘤 (vincristine) 來有效抑制愛寧達的抗藥性。我們的研究結果可以建議在面臨愛寧達的抗藥性時，使用長春花生物鹼類的化療藥物可能是有效緩解愛寧達抗藥性的方法，並且這方法不會因為 TP53 是否為野生型或突變型而有所影響。更重要的意義是長春花生物鹼類的化療藥物可以降低 ERK 蛋白激酶被磷酸化，所以會控制抗愛寧達藥物細胞的遷移和侵襲的能力。這一發現提供了新的認識來克服愛寧達抗藥性引起的癌轉移。

我們感謝國科會、科技部的審查委員對我們長期的鼓勵和支持，此申請書的目標皆已完成並且投稿到 Oncogene 且已經被接受和發表 (Title: The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids). Oncogene advance online publication, June 6, 2016; doi:10.1038/onc.2016.195 (IF=7.932 ONCOLOGY R/C=15/213=7.04%).

中文關鍵詞：愛寧達抗藥性 Pemetrexed resistance; 胸苷酸合成酶 Thymidylate synthase; 上皮-間質轉化 Epithelial-mesenchymal transition; ERK 蛋白激酶; E-cadherin 基因轉錄抑制因子 ZEB1; 長春花生物鹼 Vinca alkaloids

英文摘要：Recently, high thymidylate synthase (TS) expression has been demonstrated as major factor for pemetrexed resistance. Therefore, a clear characterization of the mechanisms to overcome pemetrexed-resistance is required. High thymidylate synthase (TS) level in cancer tissue is

considered to result in resistance to pemetrexed therapy for advanced stages of nonsquamous non-small cell lung cancers. To further investigate the mechanism of pemetrexed resistance and potential prognostic outcomes in lung cancer, we established pemetrexed-resistant lung adenocarcinoma cell sublines from CL1 harboring a mutated TP53 gene (R248W) and A549 harboring wild type TP53. We found the TS expression is upregulated in both pemetrexed-resistant sublines and the reduced TS level achieved through shRNA inhibition resulted in higher pemetrexed sensitivity. We also demonstrated that the acquisitions of pemetrexed resistance enhances epithelial - mesenchymal transition (EMT) in vivo with a mice animal model and in vitro with CL1 and A549 sublines, which was associated with upregulation of ZEB1 which, in turn, downregulates E-cadherin and upregulates fibronectin. When ERK1/2 phosphorylation was reduced by an inhibitor (U0126) or siRNA inhibition, both pemetrexed-resistant sublines reduced their migration and invasion abilities. Therefore, the ERK-mediated pathways induce apoptosis with pemetrexed treatment, and may in turn mediate EMT when cancer cells are resistant to pemetrexed. We further demonstrated that the growth of pemetrexed-resistant tumors could be inhibited by vinblastine in vivo and vincristine in vitro. Our data indicate that pemetrexed resistance could be relieved by non-cross-resistant chemotherapeutic drugs such as vinca alkaloids and might be independent to TP53 status. Furthermore, the phosphorylation of ERK was reduced by vincristine. This finding provides a new insight for overcoming pemetrexed resistance and metastasis by application of vinca alkaloids.

With the kindness support from NSC and MOST, we have completed the proposed investigations and the manuscript has been submitted with the title of (The ERK-ZEB1 pathway mediates epithelial - mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids) which has been accepted and published in *Oncogene advance online publication*, June 6, 2016; doi:10.1038/onc.2016.195 (IF=7.932 ONCOLOGY R/C=15/213=7.04%).

英文關鍵詞：Pemetrexed resistance; Thymidylate synthase; Epithelial - mesenchymal transition; ERK; ZEB1; Vinca alkaloids

科技部補助專題研究計畫成果報告

(期中進度報告/期末報告)

(計畫名稱)

計畫類別：個別型計畫 整合型計畫

計畫編號：MOST 104-2320-B-040-003-

執行期間： 2015 年 08 月 01 日至 2016 年 07 月 31 日

執行機構及系所：中山醫學大學醫學研究所

計畫主持人：許國堂

共同主持人：

計畫參與人員：Ling-Yen Chiu, I-Lun Hsin, Tsung-Ying Yang, Wen-Wei Sung, Jinghua Tsai Chang,
Jiunn-Liang Ko

本計畫除繳交成果報告外，另含下列出國報告，共 0 份：

- 執行國際合作與移地研究心得報告
- 出席國際學術會議心得報告
- 出國參訪及考察心得報告

中 華 民 國 105 年 09 月 01 日

研究計畫中文摘要: 關鍵詞: 愛寧達抗藥性 Pemetrexed resistance; 胸苷酸合成酶 Thymidylate synthase; 上皮-間質轉化 Epithelial-mesenchymal transition; ERK 蛋白激酶; E-cadherin 基因轉錄抑制因子 ZEB1; 長春花生物鹼 Vinca alkaloids

研究長春花生物鹼化療藥物對愛寧達之抗藥性肺癌細胞所引起的死亡機制

目前認為是因為胸苷酸合成酶(TS)蛋白質高量造成肺癌對愛寧達產生抗藥性，可是對如何解決愛寧達產生之抗藥性並無相關的研究。因此尋找有效的第二線化療用藥來對付具有愛寧達抗藥性之肺癌就顯得非常需要。在癌組織中高表達的胸苷酸合成酶被認為會對愛寧達的化療藥在治療晚期的非小細胞肺癌中的非鱗狀上皮癌產生抗藥性。為了深入研究愛寧達產生的抗藥性機制和可能因此會對肺癌治療的預後有重要的影響，我們使用兩株抗愛寧達藥物細胞株 A549/A400 (TP53 野生型) 和 CL1/A200 (TP53-突變型)來做為此次研究的材料。

我們首先證明了在這兩株抗愛寧達藥物細胞株中的胸苷酸合成酶(TS)都呈現高表達，如果使用干擾胸苷酸合成酶的 shRNA 來抑制胸苷酸合成酶的表達會讓抗愛寧達藥物細胞株對愛寧達產生敏感性。我們也在細胞和動物的模式下證明得到愛寧達的抗藥性會增強上皮-間質轉化所造成的轉移能力 (EMT)，這個轉移能力是透過 ZEB1 這個 E-cadherin 基因轉錄抑制因子來抑制上皮鈣粘蛋白(E-cadherin)和增加纖維結合蛋白(fibronectin)的表達。當 ERK1/2 蛋白激酶的磷酸化被其抑制劑(U0126)或是小干擾 RNA 所降低，這兩株抗愛寧達藥物細胞的遷移和侵襲的能力就顯著的減少。

我們以前曾經證明愛寧達會利用 ERK 的訊息路徑來引起肺癌細胞的凋亡，因此我們認為當經由 ERK 的訊息路徑無法引起肺癌細胞的凋亡而變成抗愛寧達藥物的肺癌細胞後，這個 ERK 的訊息路徑反而會增加肺癌細胞的轉移能力。同時，我們進一步使用另一類的化療藥敏畢瘤(vinblastine)以及敏克瘤(vincristine)來有效抑制愛寧達的抗藥性。我們的研究結果可以建議在面臨愛寧達的抗藥性時，使用長春花生物鹼類的化療藥物可能是有效緩解愛寧達抗藥性的方法，並且這方法不會因為 TP53 是否為野生型或突變型而有所影響。更重要的意義是長春花生物鹼類的化療藥物可以降低 ERK 蛋白激酶被磷酸化，所以會控制抗愛寧達藥物細胞的遷移和侵襲的能力。這一發現提供了新的認識來克服愛寧達抗藥性引起的癌轉移。

我們感謝國科會、科技部的審查委員對我們長期的鼓勵和支持，此申請書的目標皆已完成並且投稿到 **Oncogene** 且已經被接受和發表 (Title: **The ERK-ZEB1 pathway mediates epithelial-mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids**)。Oncogene advance online publication, June 6, 2016; doi:10.1038/onc.2016.195 (IF=7.932 ONCOLOGY R/C=15/213=7.04%)。

研究計畫英文摘要：

關鍵詞: Pemetrexed resistance; Thymidylate synthase; Epithelial–mesenchymal transition; ERK; ZEB1; Vinca alkaloids

Recently, high thymidylate synthase (TS) expression has been demonstrated as major factor for pemetrexed resistance. Therefore, a clear characterization of the mechanisms to overcome pemetrexed-resistance is required. High thymidylate synthase (TS) level in cancer tissue is considered to result in resistance to pemetrexed therapy for advanced stages of nonsquamous non-small cell lung cancers. To further investigate the mechanism of pemetrexed resistance and potential prognostic outcomes in lung cancer, we established pemetrexed-resistant lung adenocarcinoma cell sublines from CL1 harboring a mutated TP53 gene (R248W) and A549 harboring wild type TP53. We found the TS expression is upregulated in both pemetrexed-resistant sublines and the reduced TS level achieved through shRNA inhibition resulted in higher pemetrexed sensitivity. We also demonstrated that the acquisitions of pemetrexed resistance enhances epithelial–mesenchymal transition (EMT) *in vivo* with a mice animal model and *in vitro* with CL1 and A549 sublines, which was associated with upregulation of ZEB1 which, in turn, downregulates E-cadherin and upregulates fibronectin. When ERK1/2 phosphorylation was reduced by an inhibitor (U0126) or siRNA inhibition, both pemetrexed-resistant sublines reduced their migration and invasion abilities. Therefore, the ERK-mediated pathways induce apoptosis with pemetrexed treatment, and may in turn mediate EMT when cancer cells are resistant to pemetrexed. We further demonstrated that the growth of pemetrexed-resistant tumors could be inhibited by vinblastine *in vivo* and vincristine *in vitro*. Our data indicate that pemetrexed resistance could be relieved by non-cross-resistant chemotherapeutic drugs such as vinca alkaloids and might be independent to TP53 status. Furthermore, the phosphorylation of ERK was reduced by vincristine. This finding provides a new insight for overcoming pemetrexed resistance and metastasis by application of vinca alkaloids.

With the kindness support from NSC and MOST, we have completed the proposed investigations and the manuscript has been submitted with the title of **(The ERK-ZEB1 pathway mediates epithelial–mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids) which has been accepted and published in Oncogene advance online publication, June 6, 2016; doi:10.1038/onc.2016.195 (IF=7.932 ONCOLOGY R/C=15/213=7.04%).**

ORIGINAL ARTICLE

The ERK–ZEB1 pathway mediates epithelial–mesenchymal transition in pemetrexed resistant lung cancer cells with suppression by vinca alkaloids

L.-Y. Chiu¹, I.-L. Hsin², T.-Y. Yang³, W.-W. Sung^{4,5,6}, J.-Y. Chi¹, J.T. Chang¹, J.-L. Ko^{1,7} and G.-T. Sheu^{1,7}

High thymidylate synthase (TS) level in cancer tissue is considered to result in resistance to pemetrexed therapy for advanced stages of nonsquamous non-small cell lung cancers. To further investigate the mechanism of pemetrexed resistance and potential prognostic outcomes in lung cancer, we established pemetrexed-resistant lung adenocarcinoma cell sublines from CL1 harboring a mutated TP53 gene (R248W) and A549 harboring wild-type TP53. We found the TS expression is upregulated in both pemetrexed-resistant sublines and the reduced TS level achieved through shRNA inhibition resulted in higher pemetrexed sensitivity. We also demonstrated that the acquisitions of pemetrexed resistance enhances epithelial–mesenchymal transition (EMT) *in vivo* with a mice animal model and *in vitro* with CL1 and A549 sublines, which was associated with upregulation of ZEB1 which, in turn, downregulates E-cadherin and upregulates fibronectin. When ERK1/2 phosphorylation was reduced by an inhibitor (U0126) or siRNA inhibition, both pemetrexed-resistant sublines reduced their migration and invasion abilities. Therefore, the ERK-mediated pathways induce apoptosis with pemetrexed treatment, and may in turn mediate EMT when cancer cells are resistant to pemetrexed. We further demonstrated that the growth of pemetrexed-resistant tumors could be inhibited by vinblastine *in vivo* and vincristine *in vitro*. Our data indicate that pemetrexed resistance could be relieved by non-cross-resistant chemotherapeutic drugs such as vinca alkaloids and might be independent to TP53 status. Furthermore, the phosphorylation of ERK was reduced by vincristine. This finding provides a new insight for overcoming pemetrexed resistance and metastasis by application of vinca alkaloids.

Oncogene advance online publication, 6 June 2016; doi:10.1038/onc.2016.195

INTRODUCTION

Pemetrexed (LY231514) inhibits at least three key enzymes including thymidylate synthase (TS), dihydrofolate reductase (DHFR) and glycinamide ribonucleotide formyltransferase (GARFT).^{1,2} Inhibition of TS results in decreased turnover of dUMP to dTMP, which is necessary for DNA synthesis.³ These targets are related to the cytotoxicity of pemetrexed, because both thymidine and hypoxanthine are required to circumvent cellular death caused by pemetrexed.⁴ Intracellularly, pemetrexed is polyglutamated to the active pentaglutamide by a reaction catalyzed by folypolyglutamate synthase (FPGS). The enzyme counteracting antifolate polyglutamylolation is γ -glutamyl hydrolase (GGH).

Recently, it has been reported that TS gene expression is significantly increased in pemetrexed-resistant small cell lung cancer cell lines.⁵ Knockdown of TS expression using siRNA has enhanced pemetrexed cytotoxicity in PC6/MTA-4.0 cells. Zhang *et al.*⁶ have shown TS and DHFR were significantly increased in the four pemetrexed-resistant A549 sublines. Chen *et al.* have suggested that TS expression, rather than DHFR, may be an important predictive factor of the treatment efficacy of pemetrexed in non-small cell lung cancer (NSCLC) patients.⁷ Another report concluded that better response usually appears in patients

with a lower expression of TS by meta-analysis⁸ with a significant association between TS expression and outcomes of pemetrexed-based chemotherapy for NSCLC. Therefore, it can be concluded that upregulation of TS gene expression may have an important role in pemetrexed resistance.

Multiple studies have revealed that chemoresistance cells often acquire an epithelial–mesenchymal transition (EMT)-like phenotype.⁹ During the acquisition of EMT characteristics, epithelial cancer cells lose the expression of proteins that promote cell–cell contact, such as E-cadherin and β -catenin, and gain the expression of mesenchymal markers, such as fibronectin, vimentin and N-cadherin, leading to remodeling of the cytoskeleton and enhancement of cancer cell migration and invasion. Recently, an EMT phenotype was observed in gemcitabine-resistant pancreatic cancer cells,^{10,11} gefitinib-resistant NSCLC,¹² oxaliplatin-resistant colorectal cancer cells,¹³ paclitaxel-resistant ovarian cancer cells¹⁴ and tamoxifen-resistant breast cancer cells.¹⁵ The association of pemetrexed resistance with EMT alteration has not been reported yet and the question of how EMT is mechanistically involved in pemetrexed resistance has not been answered.

TGF- β triggers diverse cellular processes including growth arrest, tissue fibrosis and EMT.^{16,17} As a result, TGF- β activates

¹Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan; ²Inflammation Research and Drug Development Center, Changhua Christian Hospital, Changhua, Taiwan; ³Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; ⁴School of Medicine, Chung Shan Medical University, Taichung, Taiwan; ⁵Department of Medical Education, Chung Shan Medical University Hospital, Taichung, Taiwan; ⁶Department of Medical Technology, Jen-Teh Junior College of Medicine, Nursing and Management, Miaoli, Taiwan and ⁷Department of Medical Oncology and Chest Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan. Correspondence: Dr G.-T. Sheu, Institute of Medicine, Chung Shan Medical University, Research Building Room 702, No. 110, Sec. 1, Jungfuo N. Road, Taichung City 402, Taiwan.

E-mail: gtsheu@comu.edu.tw

Received 10 November 2015; revised 21 April 2016; accepted 26 April 2016

Table 1. Drug sensitivities of parental cells and drug-resistant sublines

	<i>IC₅₀ ± s.d.^a (nmol/l)</i>				
Drugs/cells	A549	A549/A400	CL1	CL1/A100	CL1/A200
Pemetrexed	1304.7 ± 94.7 (1.0)	49 333.3 ± 1755.9 (37.8)	32.1 ± 0.2 (1.0)	736.2 ± 49.1 (22.9)	2777.8 ± 481.1 (86.5)
Methotrexate	48.7 ± 0.6 (1.0)	113.3 ± 4.7 (2.3)	11.2 ± 0.2 (1.0)	12.0 ± 0.5 (1.1)	27.4 ± 1.6 (2.5)
5-FU	6000.0 ± 500.0 (1.0)	7900.0 ± 700.0 (1.3)	3980.0 ± 300.0 (1.0)	3330.0 ± 180.0 (0.8)	2460.0 ± 320.0 (0.6)
Docetaxel	6.4 ± 0.1 (1.0)	6.8 ± 0.4 (1.1)	3.1 ± 0.2 (1.0)	5.6 ± 0.8 (1.8)	6.0 ± 0.4 (1.9)
Vincristine	14.9 ± 0.1 (1.0)	4.2 ± 0.1 (0.3)	4.2 ± 0.3 (1.0)	3.3 ± 0.1 (0.8)	2.6 ± 0.4 (0.6)

Note: A549/A400 is a pemetrexed-resistant A549 subline; CL1/A100 and CL1/A200 are pemetrexed-resistant CL1 sublines. Cell survival was determined by MTT assay. (Fold resistance) was relative to the parental cell line. Pemetrexed was provided by Eli Lilly Corporation (Indianapolis, IN, USA). Docetaxel was obtained from Aventis Pharmaceuticals Inc. (Bridgewater, NJ, USA). Methotrexates (MTX), 5-fluorouracil (5-FU) and vincristine were purchased from Sigma-Aldrich (St Louis, MO, USA). ^aData are the mean ± s.d. of at least three independent experiments done in triplicate.

R-Smads (Smad2 and Smad3) via phosphorylation at their C-terminal serine residues. R-Smads form a heterocomplex with Smad4 and translocate into the nucleus to regulate gene expression.^{18–22} These pathways are referred to as Smad-dependent pathways. Snail and Slug, key regulators of TGF- β -induced EMT, are sufficient for the induction of single-cell invasion.²³ In addition to the Smad signaling pathways, TGF- β also elicits diverse types of non-Smad signaling pathways. Among them, activation of Ras, mitogen-activated protein kinases (MAPKs) such as ERK and p38MAPK (p38), Rho GTPases, and PI3K/Akt signaling has been linked to TGF- β -induced EMT.^{24–26} Recent studies have identified the crucial role of TGF- β signaling pathways in inducing EMT through the Smad-dependent and Smad-independent pathways.^{17,27–29}

Transcription factors involved in EMT such as Snail, Slug, TWIST and the ZEB families mainly repress expression of E-cadherin during EMT.^{30–33} The transcription factor ZEB1 can be activated by the TGF- β , TNF- α and IGF1 signaling pathways. A correlation of ZEB1 expression and loss of E-cadherin has been demonstrated in tumor cell lines of lung adenocarcinomas.³⁴ Therefore, ZEB1 is also a crucial mediator of EMT, exerting its effects on induction of EMT by inhibiting expression of E-cadherin.

Finding a way to control the growth of pemetrexed-induced resistance in lung cancer cells is clinically important. However, it has been reported that pemetrexed-resistant lung cancer sublines show cross-resistance to cisplatin, but not to docetaxel, vinorelbine and 5-fluorouracil,⁶ which points to the possibility of reversing pemetrexed resistance by using another clinically chemotherapeutic drug. In this study, we have identified the signaling pathway that controls pemetrexed-induced EMT. Furthermore, we also provide evidence that vinca alkaloids, a group of clinically used anti-cancer drugs, reversed the pemetrexed resistance and EMT. These findings may be applied immediately to overcome pemetrexed resistance.

RESULTS

Establishment of pemetrexed resistant CL1 and A549 lung cancer sublines

According to MTT sensitivity assay, the established A549/A400, CL1/A100 and CL1/A200 sublines (Table 1) revealed their drug sensitivities in terms of *IC₅₀* (inhibition concentration). The A549/A400, CL1/A100 and CL1/A200 sublines have 37.8-fold, 22.9-fold and 86.5-fold resistance to pemetrexed, respectively, when compared with parental cells. To investigate whether pemetrexed resistance may result in cross-resistance to other antimetabolic chemotherapy, the sensitivities to MTX and 5-FU were also determined and only minimal resistances were detected. For example, the CL1/A200 subline is 2.5-fold resistant to MTX and 0.6-fold resistant to 5-FU. The drug sensitivity profiles of the A549 and CL1 sublines in our study exhibit similar results to

those previously reported for PC-9 and A549 pemetrexed-resistant sublines.⁶ Interestingly, all three pemetrexed-resistant sublines have only a low degree of cross-resistance to docetaxel (1.1–1.9-fold). Moreover, the pemetrexed-resistant sublines all showed a significant sensitivity to vincristine when compared with parental A549 (0.3-fold) and CL1 (0.6–0.8-fold) cells.

Characterization of the pemetrexed-regulated genes

To investigate the mechanism of the pemetrexed resistance, we compared the expression of pemetrexed-target proteins TS and DHFR, as well as the expression of the enzymes FPGS and GGH by western blot analysis. The protein levels of TS and DHFR significantly increased in A549/A400 (Figure 1a), CL1/A100 and CL1/A200 sublines (Figure 1b). The levels of FPGS were slightly increased in all three sublines. Upregulated GGH levels in A549/A400 cells and downregulated GGH levels in CL1 sublines were observed. It has been reported that the level of TS protein determines pemetrexed sensitivity in cell lines^{6,35} and lung cancer tissues.⁷ Therefore, to demonstrate the dominant role of TS overexpression in the acquired pemetrexed resistance, the sublines were infected with the shRNA expressing lentivirus that targets TS mRNA. Three shTS constructs significantly inhibited TS expression when compared with the shGFP control and the proteins of TS were detected by western blotting. The pemetrexed sensitivities were enhanced in shTS-infected CL1/A100 (Figure 1c), and CL1/A200 (Figure 1d) sublines were measured by MTT cell survival assay. When TS protein expression was reduced, the viabilities of CL1/A100 and CL1/A200 cells were coordinately reduced with pemetrexed treatment. We also further investigated whether the 5-FU and MTX sensitivities could be affected by TS inhibition. From the results of MTT assay, the drug sensitivities of MTX (Figure 1e) and 5-FU (Figure 1f) in the TS-inhibited CL1/A200 subline were not altered significantly. Our data demonstrate that high levels of TS expression are associated with pemetrexed resistance. Inhibition of TS expression by shRNA enhances pemetrexed sensitivity, but not sensitivity to MTX and 5-FU.

Acquisition of pemetrexed resistance promotes metastasis *in vivo*

To answer whether pemetrexed resistance may result in lung cancer metastasis, we injected the A549/A400 and parental A549 cells through the tail vein of SCID mice. Although all A549-injected and A549/A400-injected animals developed lung tumors, a greater number and larger size of tumors were found in the animal group injected with A549/A400 cells and the weights of the tumors were significantly higher (Figure 2a) in the pemetrexed-resistant A549/A400-injected animals. The lung tissues were further examined with hematoxylin and eosin (H&E) staining for tumor verification and higher TS expressions were detected in A549/A400 tumors by immunohistochemistry (IHC; Figure 2b).







Figure 1. Characterization of the pemetrexed-resistant A549 and CL1 lung cancer cells. The expression of TS, DHFR, FPGS and GGH were detected by western blot assay in A549 (a) and CL1 (b) sublines. Inhibition of TS by shRNA in CL1/A100 (c) and CL1/A200 (d) sublines were followed by MTT assay. The sensitivities of TS-inhibited CL1 sublines to MTX treatment were examined by MTT assay (e) and 5-FU (f). * $P < 0.05$ was considered statistically significant. Individual clones are identified by their unique TRC number, which were purchased from National RNAi Core Facility at Academia Sinica, Taiwan. To inhibit TS expression, the CL1 sublines (5×10^6 per well) were sub-cultured onto 60-mm plates. After 16 h of incubation at 37 °C, cells were infected with recombinant lentivirus vectors with protamine sulfate added (0.8 μ g/ μ l) to help infection. The next day, the medium was removed and the cells were selected by 2 μ g/ml puromycin (Sigma, P8833) at 37 °C for 48 h, followed by MTT assay or protein detection. The clone of shGFP (TRCN0000072178) for vector control targeted to GFP, whereas the clones of shTS-1 (TRCN0000291720), shTS-2 (TRCN0000291655) and shTS-3 (TRCN0000045665) targeted to TS.



The CL1 and CL1/A200 cells were also injected into SCID mice to test their metastatic potential. As low metastasis of the CL1 cells has been demonstrated,³⁶ it is not surprising that none of the CL1-injected animals developed metastasis and only two of the CL1/A200-injected animals developed lung metastasis at 75 days when compared with the lungs of CL1-injected animals (Figure 2c). The H&E staining and high TS expression confirmed the CL1/A200 cells have metastatic potential.

Pemetrexed-resistant sublines show changed EMT molecular markers *in vitro* and *in vivo*

In order to further support the metastatic potential of pemetrexed-resistant sublines detected in the mice model, *in vitro* assays were performed using transwell cell culture chambers to compare the migration and invasion abilities of parental cells and sublines. The pemetrexed-resistant A549/A400 cells showed a 3.5-fold increase in migration with 4 h incubation (Figure 3a) and a 3.2-fold increase in invasion with 16 h incubation (Figure 3b) through the transwell membrane when compared with parental cells. Similar results also revealed that CL1/A100 and CL1/A200 have significant 2.7-fold increases in migration with 24 h incubation (Figure 3c). Both CL1 sublines also have 2.8-fold and 3.7-fold increases in invasion abilities, respectively, with 48 h incubation (Figure 3d). Therefore, we examined whether the induced EMT found in pemetrexed-resistant sublines came through Smad-dependent or Smad-independent pathways by western blot analysis in all three sublines and compared the results with those of their parental cells with known EMT markers (Figure 3e). According to the data, the expression of E-cadherin protein levels were downregulated but the phosphorylated Smad2 and Smad3 levels were not significantly increased in pemetrexed-resistant sublines, nor were the protein levels of Slug and Snail. Only phosphorylated p38 and ERK levels were highly upregulated along with ZEB1 and fibronectin levels. The results indicate p38 and/or ERK signaling pathways may regulate EMT through a Smad-independent pathway. Pemetrexed-resistant sublines that developed EMT were correlated with downregulated E-cadherin, and upregulated Fibronectin and ZEB1. To better understand the development of EMT in pemetrexed resistance, we compared the morphologic appearances of low and high doses pemetrexed-selected stable cell lines of A549 and CL1 cells (A549/A200 and A549/A400, CL1/A50 and CL1/A200, respectively). The parental A549 and CL1 cells changed from a classical epithelial morphology to a mesenchymal, spindle-shaped morphology (Supplementary Figure 1a). Although the spindle-shaped morphology in high-dose pemetrexed-selected cells (A549/A400 and CL1/A200) was not obviously as low-dose pemetrexed-selected cells (A549/A200 and CL1/A50), the expression levels of E-cadherin and fibronectin were further confirmed through western blotting of total cell lysates (Supplementary Figure 1b). The western blots confirmed downregulation of E-cadherin and upregulation of fibronectin expression. Furthermore, the levels of pERK and ZEB1 were also upregulated in all pemetrexed-resistant sublines. Fos family member FRA1 is one of the most frequently overexpressed AP-1 proteins in solid cancers, ERK2/FRA1 induce EMT via regulation of ZEB protein expression.³⁷ Interestingly, only FRA1 levels in A549 sublines were significantly increased (Supplementary Figure 1b).

To verify the expressions of E-cadherin, ZEB1, pERK and fibronectin in the lung tumors, the tumor sections of A549 and A549/A400 cells were evaluated with individual antibody (Figure 2b). The IHC results clearly demonstrate a reduction in surface expression of E-cadherin and upregulation of pERK, ZEB1 and fibronectin. High-magnification pictures of IHC are provided in Supplementary Figure 5.

Regulation of EMT and MAPK signaling

The mechanisms of pemetrexed-resistant-induced EMT were further investigated by inhibition of ERK1/2 phosphorylation with U0126 and p38 phosphorylation with SB253580 followed by Western blot analysis. In the A549/A400 subline, the reduced levels of phosphorylated-ERK (pERK) by U0126 were correlated with reduced ZEB1 and fibronectin expression as well as upregulated E-cadherin expression. In contrast, inhibition of p38 by SB253580 had no effect on ZEB1, fibronectin and E-cadherin expression. Although the p-p38 levels were not significantly reduced by SB253580, we have checked the downstream p38-regulated protein Activating transcription factor 2 (ATF-2)³⁸ and found the levels of phosphorylated ATF-2 significantly reduced by SB253580 after one hour. The inhibitor PD98059 specifically inhibits MEK-1-mediated activation of MAPK which does not directly inhibit ERK. This also caused reduced p-ERK and ZEB1 levels combined with upregulated E-cadherin expression (Figure 4a). To test the toxicities of kinase inhibitors, we treated individual subline with indicated inhibitor for 24 h and the cell viability was determined by MTT assay (Figures 4b and f). Inhibition of ERK phosphorylation resulted in A549/A400-reduced migration (Figure 4c) and invasion abilities (Figure 4d) of 50%, whereas inhibition of p38 only had a residual effect. Similar to the results obtained from A549/A400 investigation, inhibition of ERK1/2 phosphorylation with U0126 and PD98059 in CL1/A200 subline reduced p-ERK, ZEB1 and fibronectin levels in combination with upregulated E-cadherin expression (Figure 4e). Inhibition of ERK phosphorylation resulted in CL1/A200-reduced migration (Figure 4g) and invasion abilities (Figure 4h) of ~50%.

Interference of ERK, ZEB1 and fibronectin expressions resulted in EMT suppression

The role of ERK1/2 in pemetrexed resistance-induced EMT was further characterized by inhibition of ERK1/2 expression with siRNA interference. In A549/A400 cells, when ERK1/2 expression was downregulated by siRNA to < 50%, E-cadherin expression was significantly increased with reduced ZEB1 and fibronectin expression (Figure 5a). The migration ability of the ERK interfered A549/A400 cells was reduced to 30% (siERK#1) and 10% (siERK#2) when compared with the si-controlled cells (Figure 5b). When invasion ability was assayed, the abilities of siERK#1 and siERK#2 cells were reduced to 40% and 10%, respectively (Figure 5c). We also investigated the effect of p-38 in pemetrexed-resistant sublines by siRNA interference (Figure 5d). The results showed that the levels of ZEB1, E-cadherin and fibronectin were not significantly altered in A549/A400 cells. Furthermore, inhibition of p-38 expression by siRNA has no effect in migration and invasion abilities *in vitro* (Figures 5e and f). Similar approaches were also applied to CL1/A200 cells (Supplementary Figures 2a-f) and

Figure 2. Investigation of the pemetrexed-induced metastasis by a mice metastasis model. The cells of A549/A400 and A549 were tail-vein injected into mice followed by monitoring for 55 days until sacrifice. The lung tissues were examined for tumor metastasis and the weights of the two groups were recorded and listed (a). H&E and IHC of TS staining were applied to verify the tumors and TS overexpression followed by pERK, ZEB1, E cadherin and fibronectin detection (b). All five CL1-injected mice were free of tumors and two of the CL1/A200-injected mice established metastatic tumors, which were stained with H&E and IHC with anti-TS antibody (c).




Figure 3. Analysis of the pemetrexed-induced metastasis *in vitro*. The cells of A549 and A549/A400 were added into transwells for 4 h incubation to determine the migration ability (a) or for 16 h to measure invasion ability (b). The cells of CL1, CL1/A100 and CL1/A200 were added into transwells for 24 h incubation to determine the migration ability (c) or for 48 h to measure invasion ability (d). Western blot analyses were applied to examine the associated signaling pathways regulating EMT in A549 and CL1 sublines (e).

reduced ERK expression also resulted in reduced ZEB1 and fibronectin expression with E-cadherin upregulation. Interference of ERK expression also reduced CL1/A200 cells migration and invasion abilities, respectively. As shown in the data in Figure 5a and Supplementary Figure 2a, the degrees of ERK inhibition were correlated with the levels of ZEB1 and fibronectin downregulation, and were also reflected in the degrees of migration and invasion inhibition. To determine the role that ZEB1 has in pemetrexed-

mediated EMT, siRNA inhibition of ZEB1 (siZEB1) was applied and the E-cadherin level was increased and the fibronectin level was decreased significantly without affecting ERK phosphorylation (Figure 5g). Inhibition of ZEB1 expression also resulted in migration (Figure 5h) and invasion (Figure 5i). Similar results were obtained from CL1/A200 cells showing that upregulated E-cadherin and downregulated fibronectin resulted in less migration and invasion under ZEB1 inhibition (Supplementary Figures 2g–i).

When fibronectin was inhibited by siRNA (siFN), ZEB1 and E-cadherin levels were not altered (Figure 5j) but migration (Figure 5k) and invasion (Figure 5l) were significantly reduced to

< 50%. Similar data were demonstrated in CL1/A200 cells (Supplementary Figures 2j-l). We conclude that pemetrexed-mediated EMT occurs via ERK-signaling activation of ZEB1, which




Figure 4. Determination of the ERK signaling pathway that regulates pemetrexed-induced EMT by kinase inhibitors. The cells of A549/A400 were treated with U0126, PD98059 and SB253580 for the indicated time and then harvested for western blot analysis. The phosphorylated ERK and p38 levels indicated the effects of kinase inhibition. The levels of ZEB1, E-cadherin and fibronectin represent the alteration of EMT upon phosphorylation inhibition (a). The possible toxicity of kinase inhibitors were measured by MTT assay (b, f). The A549/A400 cells were pretreated with the indicated kinase inhibitor for 24 h followed by migration assay (c) or invasion assay (d). The CL1/A200 cells were treated with individual kinase inhibitors for the indicated time, followed by protein detection (e). The kinase inhibitor pretreated CL1/A200 cells were analyzed by transwell migration assay (g) or invasion assay (h). U0126, PD98059 and SB253580 were purchased from Cell Signaling (Danvers, MA, USA).

downregulates E-cadherin and upregulates fibronectin to promote EMT in both A549/A400 and CL1/A200 pemetrexed-resistant cancer cells.

To answer whether overexpressed TS also contribute to ERK/ZEB1-mediated EMT, we used siRNA to inhibit TS in A549/A400 and CL1/A200 cells (Supplementary Figure 3). Inhibition of TS




Figure 5. Inhibition of ERK by siRNA technology to correlate the EMT suppression in pemetrexed-resistant sublines. The cells of A549/A400 were transfected with two different sequences of siRNA to inhibit ERK expression (siERK#1 and siERK#2). After 48 h incubation, the cells were harvested for pERK, ERK, ZEB1, E-cadherin and fibronectin protein detection (a) or seeded for migration assay (b) and invasion assay (c). Similarly, the expression of p38 was inhibited by two individual siRNAs and examined (d–f). A mixture of ZEB1 siRNAs were transfected into A549/A400 cells and the effects of inhibited ZEB1 were analyzed by western blot (g), migration (h) and invasion (i) assays. Similarly, fibronectin siRNAs were transfected into cells and analyzed (j–l), respectively. A mixed siRNA for ZEB1 (5AS1_Hs02_00330526, 00330527, 00330528, 00330529) and fibronectin (5AS1_Hs01_00203291, Hs02_00203292, Hs02_00203294, Hs02_00333045) with siC (universal NC control siRNA) were used. siRNAs for p38 (#6243 and #6564) were purchased from Cell Signaling.

expression in pemetrexed-resistant A549/A400 cells by siRNA resulted in loss of cell proliferation as sub-G1 fraction significantly increased (Supplementary Figure 3d). The TS-inhibited cells further reduced migration and invasion (Supplementary Figures 3b and c), but not the ERK phosphorylation (Supplementary Figure 3a). The levels of ZEB1, E-cadherin and fibronectin were not altered in TS-inhibited cells. Inhibition of TS expression in CL1/A200 cells by siRNA has no major effects on cell proliferation, migration and invasion (Supplementary Figures 3e–h).

Vinblastine inhibits pemetrexed-resistant tumor growth in a mice xenograft model and may also inhibit EMT

According to the data listed in Table 1, pemetrexed-resistant sublines were more sensitive to vincristine than their parental cells. Therefore, we tested the efficacy of vinblastine in a mice xenograft model inoculated with A549/A400 cells. Compared with the PBS or pemetrexed treatment, vinblastine significantly inhibited the growth of A549/A400 tumors (Figure 6a). We then examined whether vincristine could also attenuate the phosphorylation of ERK1/2 and suppress EMT. When A549/A400 cells were treated with vincristine (5 nM) for 24 h, ERK and p-ERK levels were reduced to 70%. With 48 h treatment, ERK and p-ERK levels were reduced to 70% and 40% respectively, when correlated with fibronectin downregulation (Figure 6b). The mRNA levels of ZEB1, E-cadherin and fibronectin in A549/A400 cells were determined by RT-PCR (Figure 6c). The mRNA levels of ZEB1 and fibronectin were reduced, and E-cadherin levels were increased significantly. Similar results were also obtained from CL1/A200 cells treated with vincristine (Supplementary Figure 4). The results indicate that vincristine inhibits the ERK signaling pathway on ERK expression and activation. Surprisingly, E-cadherin levels were not correspondingly upregulated when ZEB1 was reduced. We speculate that vincristine induces A549/A400 cell death. This might result in E-cadherin degradation. Because pemetrexed-resistant cells are sensitive to vincristine treatment, it is difficult to recognize the possible effect on EMT inhibition; therefore, we used 5 nM of vincristine to treat A549/A400 cells for *in vitro* transwell assays. With 24 h of vincristine treatment, the viability of vincristine-treated cells was maintained at ~90% when compared with untreated cells (Figure 6d). Under a non-lethal dose of vincristine treatment, the migration of A549/A400 cells was reduced to 50% (Figure 6e), and the invasion ability was also reduced to 50% (Figure 6f). These results indicate that vincristine and vinblastine not only overcome pemetrexed resistance but also may suppress ERK–ZEB1 regulated metastasis in NSCLC. In summary, as shown in Figure 6g, we have demonstrated that the enhanced pemetrexed resistance of EMT is mediated by ERK and ZEB1, and vinca alkaloids may resolve resistance and reduce metastasis.

DISCUSSION

Previously, we have identified pemetrexed-mediated apoptosis associated with the activation of ataxia telangiectasia mutated/TP53-dependent and -independent signaling pathways, which promote intrinsic and extrinsic apoptosis.³⁹ However, when lung cancer cells develop pemetrexed resistance, researchers have yet to study whether TP53 status could affect the mechanism of pemetrexed resistance. Up to date, there is no clear evidence showing how to resolve resistance occurring after pemetrexed treatment. Our data suggested that the choice of docetaxel to manage first-line pemetrexed resistance could be suggested and there is no obvious bias against the status of TP53 in pemetrexed-resistant sublines of docetaxel sensitivities.

Chemoresistance is usually accompanied with metastasis that blocks the efficiency of cancer therapy. Our data demonstrated that wt-TP53 and mut-TP53 lung cancer cells increased their metastatic potential after pemetrexed selection. In the mice

metastasis model (Figure 2), enhanced metastasis can be observed in A549/A400 cells, which developed more tumors in the lung tissue. In contrast to the highly mobile A549 cells, CL1 cells showed no metastatic abilities and did not establish any tumors in mice lungs. Therefore, when low percentage of CL1/A200 cells established tumors *in vivo*, it suggested that metastasis can be induced by pemetrexed resistance. We have shown that pemetrexed-induced apoptotic cell death is ERK-dependent.⁴⁰ It is possible that the surviving cells using high TS expression to tolerate pemetrexed-activated ERK signaling and resulted in metastasis. Indeed, the *in vitro* migration and metastasis assays further support that pemetrexed-mediated EMT is associated with ERK/ZEB1 activation and E-cadherin inhibition as well as upregulation of fibronectin (Figure 4). Although p38 also activated in pemetrexed resistant cells, this signaling pathway has no effect on pemetrexed-mediated EMT. Previously, ERK2/FRA1 induce EMT via regulation of ZEB protein expression has been shown.³⁷ Although the si-RNAs used for ERK1/2 inhibition in our investigation cannot distinguish ERK1 or ERK2 specifically, our data further support the importance of this signaling pathway in pemetrexed-resistant-induced EMT. Activation of ZEB1 to repress E-cadherin expression has been shown,⁴¹ but the association of ZEB1 and fibronectin upregulation is a novel finding. We found that FRA1 was strongly expressed in A549/A400 but not CL1/A200 cells. We suggest that FRA1 may be a critical ERK pathway effector regulating EMT-like changes in A549/A400 cells. What could be the linking factor between ERK and ZEB1 for EMT in CL1/A200 cells? As relative low FRA1 level was detected in CL1/A200 cells, upregulated ZEB1 expression may be resulted from β -catenin signaling.⁴²

There are four major vinca alkaloids in clinical use: vinblastine (VBL), vinorelbine (VRL), vincristine (VCR) and vindesine (VDS). VCR, VBL and VRL have been approved for use in the United States.⁴³ However, these drugs are a substrate of the ABCB1 (P-gp) transporter, therefore overexpression of ABCB1 in cancer cells is considered the major phenotype of multidrug resistance to vinca alkaloids.^{44,45} We have shown that vinca alkaloids are non-cross-resistant to pemetrexed and may be applied to reverse pemetrexed resistance of NSCLC. A retrospective study to evaluate the activity and toxicity of VRL administered to a consecutive series of pemetrexed-pretreated malignant pleural mesothelioma patients (59 patients) has been reported.⁴⁶ It seems that VRL is moderately active in pemetrexed-pretreated malignant pleural mesothelioma patients, with an acceptable toxicity profile.

We have suggested that the ERK-mediated pathway is an important regulator of pemetrexed-induced apoptotic cell death.⁴⁰ The surviving cancer cells with upregulated TS may enhance EMT via the ERK/ZEB1 signaling pathway and result in metastasis. Our study demonstrated that pemetrexed resistance could be relieved by vinca alkaloids and might be independent to the TP53 status.

MATERIALS AND METHODS

Cell culture

Human lung adenocarcinoma cells CL1 harboring a mutated TP53 gene (mut-TP53, R248W) were cultured in RPMI-1640 medium with 10% fetal bovine serum (Gibco, Life Technologies, Carlsbad, CA, USA). Human adenocarcinoma A549 cells (ATCC, Manassas, VA, USA) harboring wild-type TP53 (wt-TP53) were maintained as previously described.⁴⁷

Cytotoxicity assay: MTT assay

Chemosensitivity to pemetrexed was determined using MTT assay. The detailed steps of MTT assay have been previously described.⁴⁷ The cells were exposed to various concentrations of pemetrexed in fresh medium for 72 h. Mean values were calculated from three independent experiments.




Figure 6. Vinblastine inhibits mice xenografted A549/A400 tumor growth and vincristine reduces phosphorylation of ERK. The A549/A400 cells were injected subcutaneously. Twelve animals were then randomly divided into three groups (PBS, VBL and pemetrexed). VBL was obtained from Teva Pharmaceutical Industries Limited (Petah Tikva, Israel). Tumor sizes were measured every 3 days following drug injection and tumor volume was calculated by the following formula: $0.5 \times \text{larger diameter (mm)} \times \text{small diameter}^2 \text{ (mm)}$. Due to tumor size variability, a non-parametric Mann-Whitney U test was applied for statistical analysis. (a). * $P < 0.05$ was considered statistically significant. The effects of VCR on A549/A400 cells were investigated by western blot analysis (b). The mRNA levels of ZEB1, E-cadherin and fibronectin were analyzed by RT-PCR (c). The cell viability with VCR (5 nM) was examined by MTT assay (d). The effects of VCR on migration (e) and invasion were determined (f). A signaling pathway that is regulated by vinca alkaloids in pemetrexed-resistant lung cancer cells is proposed (g).

Protein extraction and western blot analysis

Protein extracts were prepared as described previously.⁴⁷ Transferred proteins (10–30 μg) on polyvinylidene difluoride membrane were reacted with polyclonal anti-TS (Santa Cruz Biotechnology, Santa Cruz, CA, USA),

anti-DMR, FPGS, GGH (GeneTex, Hsinchu City, Taiwan), anti-β-actin (NeoMarker, Fremont, CA, USA), anti-p38, -pERK, -p/JNK, -Zeb1, -E-cadherin, -Fibronectin, -Smad2/3, -p-ATF-2 (Thr71), -FRA1 (Cell Signaling, Danvers, MA, USA) and anti-Tp53 (DAKO, Glostrup, Denmark) separately,

followed by conjugation of anti-rabbit or anti-mouse IgG (Santa Cruz Biotechnology) to horseradish peroxidase.

Inhibition of ERK, ZEB1 and fibronectin by siRNA transfection

The cells (8×10^6) were seeded in six-well plates for 16 h. The siRNA (30 pmol) for ERK (Sigma, siErk#1 SASI_Hs01_00104111; siErk#2 SASI_Hs01_00104113) were transfected with Lipofectamine RNAiMAX reagent (Invitrogen, Carlsbad, CA, USA) for 4 h and then replaced with fresh culture medium and incubated for an additional 48 h. The cells were dissociated by trypsin/EDTA solution and reseeded for migration assay, or harvested with RIPA buffer for western blots analysis. Similar procedures were applied to inhibition of ZEB1, fibronectin and p38.

Mice metastasis and xenograft models

Cells were washed and resuspended in PBS. Subsequently, 4- to 6-week-old SCID mice ($n = 5$ per group; BioLASCO Taiwan Co., Ltd., Taipei, Taiwan) were injected in the lateral tail vein with a single-cell suspension containing 5×10^5 cells of A549 and subline in 50 μ l PBS buffer or 2×10^6 cells of CL1 and subline. Mice were killed after 55 days (A549) and 75 days (CL1). All organs were examined for metastasis formation. The lungs were removed and fixed in 10% formalin fixative. The tumor weights were measured on a microbalance. The representative lung tumors were removed, fixed and embedded in paraffin, which was then sectioned into 4 μ m layers and stained with H&E for histologic analysis and IHC with the indicated antibody and photography. The current study was approved by the Chung Shan Medical University Animal Care Committee (permit number: 1542) and all efforts were made to minimize suffering. To establish A549/A400 tumor xenografts, male BALB/c mice were injected subcutaneously with 5×10^6 cells (100 μ l in serum-free DMEM) plus 100 μ l Matrigel (BD Biosciences, San Jose, CA, USA). Twelve animals were then randomly divided into three groups consisting of four animals each. Thirty days after cell implantation, when the tumor size reached 120 mm³, mice in each group were intraperitoneally injected with 100 μ l PBS and pemetrexed (100 mg/kg per mouse per week) to serve as controls. The VBL group was injected with 4.8 mg/kg per mouse per week.

In vitro transwell migration assay

Cell migration assay was carried out in 24-well tissue culture plates filled with 1.5 ml DMEM (for A549 cells) or RPMI (for CL1 cells) containing 10% FBS with a 8- μ m transwell filter membrane (Thermo Fisher, Waltham, MA, USA). The group of A549 cells (2×10^4 cells/100 μ l) in DMEM containing 0.5% FBS were added to transwell plates and incubated in 5% CO₂ at 37 °C for 4 h. We fixed the cells on the lower side of the insert filter quickly with ice-cold methanol for 30 min. The cells were dried at room temperature and then were stained with 20% Giemsa solution (Merck KGaA, Darmstadt, Germany) overnight. Once stained, the cells were observed by using the optical microscope and photography. Similar procedures were applied to CL1 cells (5×10^4 cells/100 μ l) incubated for 24 h.

In vitro transwell matrigel invasion assay

Invasion of tumor cells was evaluated with procedures similar to those of migration assay with matrigel (BD Biosciences cat. no. 354234) added. In medium-containing plates with a membrane, 0.5 μ g/150 μ l of matrigel for A549 cells and 0.2 μ g/150 μ l of matrigel for CL1 cells were added and polymerized at 37 °C for 3 h. The groups of A549 cells (2×10^4 cells/100 μ l) were incubated for 16 h and CL1 cells (5×10^4 cells/100 μ l) were incubated for 48 h. After the indicated time, non-invasive cells were gently removed from the top of the matrigel with a cotton-tipped swab. Invasive cells were fixed in ice-cold methanol, stained with 20% Giemsa solution and counted under a microscope. Results were averaged from three independent experiments.

Statistical analysis

All values are presented as mean \pm s.d. Data were compared among groups using a t-test and * $P < 0.05$ is considered statistically significant.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported by grants from the Ministry of Science and Technology, Taiwan (MOST-103-2320-B-040-015, MOST-104-2320-B-040-003).

REFERENCES

- 1 Rollins KD, Lindley C. Pemetrexed: a multitargeted antifolate. *Clin Ther* 2005; **27**: 1343–1382.
- 2 Calvert H, Bunn PA Jr. Future directions in the development of pemetrexed. *Semin Oncol* 2002; **29**: 54–61.
- 3 Schultz RM, Patel VF, Worzalla JF, Shih C. Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. *Anticancer Res* 1999; **19**: 437–443.
- 4 Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. *Cancer Res* 1997; **57**: 1116–1123.
- 5 Ozasa H, Oguri T, Uemura T, Miyazaki M, Maeno K, Sato S et al. Significance of thymidylate synthase for resistance to pemetrexed in lung cancer. *Cancer Sci* 2010; **101**: 161–166.
- 6 Zhang D, Ochi N, Takigawa N, Tanimoto Y, Chen Y, Ichihara E et al. Establishment of pemetrexed-resistant non-small cell lung cancer cell lines. *Cancer Lett* 2011; **309**: 228–235.
- 7 Chen CY, Chang YL, Shih JY, Lin JW, Chen KY, Yang CH et al. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed. *Lung Cancer* 2011; **74**: 132–138.
- 8 Liu Y, Yin TJ, Zhou R, Zhou S, Fan L, Zhang RG. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis. *Cancer Chemother Pharmacol* 2013; **72**: 1125–1132.
- 9 Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, Banerjee S et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. *Drug Resist Updat* 2010; **13**: 109–118.
- 10 Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. *Ann Surg Oncol* 2007; **14**: 3629–3637.
- 11 Wang Z, Li Y, Kong D, Banerjee S, Ahmad A, Azmi AS et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. *Cancer Res* 2009; **69**: 2400–2407.
- 12 Rho JK, Choi YJ, Lee JK, Ryou BY, Na II, Yang SH et al. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. *Lung Cancer* 2009; **63**: 219–226.
- 13 Yang AD, Fan F, Camp ER, van Buren G, Liu W, Somcio R et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. *Clin Cancer Res* 2006; **12**: 4147–4153.
- 14 Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. *Int J Oncol* 2007; **31**: 277–283.
- 15 Hiscox S, Jiang WG, Obermeier K, Taylor K, Morgan L, Burmi R et al. Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of beta-catenin phosphorylation. *Int J Cancer* 2006; **118**: 290–301.
- 16 Plek E, Moustakas A, Kurisaki A, Heldin CH, ten Dijke P. TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. *J Cell Sci* 1999; **112**: Pt 24 4557–4568.
- 17 Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. *Cancer Sci* 2007; **98**: 1512–1520.
- 18 Akiyoshi S, Inoue H, Hanai J, Kusanagi K, Nemoto N, Miyazono K et al. c-Ski acts as a transcriptional co-repressor in transforming growth factor-beta signaling through interaction with smads. *J Biol Chem* 1999; **274**: 35269–35277.
- 19 Heldin CH, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins. *Nature* 1997; **390**: 465–471.
- 20 Nishihara A, Hanai JI, Okamoto N, Yanagisawa J, Kato S, Miyazono K et al. Role of p300, a transcriptional coactivator, in signalling of TGF-beta. *Genes Cells* 1998; **3**: 613–623.
- 21 Massague J, Chen YG. Controlling TGF-beta signalling. *Genes Dev* 2000; **14**: 627–644.
- 22 Feng XH, Derynck R. Specificity and versatility in tgf-beta signaling through Smads. *Annu Rev Cell Dev Biol* 2005; **21**: 659–693.
- 23 Wakefield LM, Hill CS. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. *Nat Rev Cancer* 2013; **13**: 328–341.
- 24 Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration. *J Cell Sci* 2002; **115**: 3193–3206.

25. Torres AJ, Mercado-Pimeriel ME, Ruryan FB, Kisten GT. TGF-beta-mediated RhoA expression is necessary for epithelial-mesenchymal transition in the embryonic chick heart. *Dev Dyn* 2006; **235**: 1589–1598.
26. Xie L, Liu JK, Chytil AM, Brown KA, Aakre ME, Moses HL. Activation of the Erk pathway is required for TGF-beta1-induced EMT *in vitro*. *Neoplasia* 2004; **6**: 603–610.
27. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. *Nature* 2003; **425**: 577–584.
28. Davies M, Robinson M, Smith E, Huntley S, Prime S, Paterson I. Induction of an epithelial to mesenchymal transition in human immortal and malignant keratinocytes by TGF-beta1 involves MAPK, Smad and AP-1 signalling pathways. *J Cell Biochem* 2005; **95**: 918–931.
29. Valcourt U, Kowmitz M, Niimi H, Heldin CH, Moustakas A. TGF-beta and the Smad signaling pathway support transcriptional reprogramming during epithelial-mesenchymal cell transition. *Mol Biol Cell* 2005; **16**: 1987–2002.
30. Balle E, Sancho E, Franco C, Dominguez D, Morfot M, Baulista J et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. *Nat Cell Biol* 2000; **2**: 84–89.
31. Cano A, Perez-Moreno MA, Rodrigo I, Lecio A, Blanco MJ, del Barrio MG et al. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. *Nat Cell Biol* 2000; **2**: 76–83.
32. Takkanen M, Grenman R, Hukkanen M, Korhonen M, Garcia de Herreros A, Virtanen I. Snail-dependent and -independent epithelial-mesenchymal transition in oral squamous carcinoma cells. *J Histochem Cytochem* 2006; **54**: 1263–1275.
33. Yee DS, Tang Y, Li X, Liu Z, Guo Y, Ghaffar S et al. The Wnt inhibitory factor 1 restoration in prostate cancer cells was associated with reduced tumor growth, decreased capacity of cell migration and invasion and a reversal of epithelial to mesenchymal transition. *Mol Cancer* 2010; **9**: 162.
34. Ohira T, Gerritall RM, Ferguson R, Kuy S, Roche J, Brambila E et al. WNT7a induces E-cadherin in lung cancer cells. *Proc Natl Acad Sci USA* 2003; **100**: 10429–10434.
35. Bujque A, Aresti U, Calvo B, Sh Mahalingam J, Munoz A, Carrera S et al. Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells. *PLoS One* 2013; **8**: e63338.
36. Chu YW, Yang PC, Yang SC, Shyu YC, Hsueh HJ, Wu R et al. Selection of invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. *Am J Respir Cell Mol Biol* 1997; **17**: 353–360.
37. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blemis J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEE1 motif-dependent signaling events. *Mol Cell* 2010; **38**: 114–127.
38. Owens DM, de Rudder ND, van der Zon GC, Carter AP, Schouten J, van der Burg C et al. Growth factors can activate ATRF via a two-step mechanism: phosphorylation of Thr71 through the Ras-MEK-ERK pathway and of Thr69 through Raf/GDS-Src-p38. *EMBO J* 2002; **21**: 3782–3793.
39. Yang TY, Chang GC, Chen KC, Hung HW, Hsu KH, Wu CH et al. Pemetrexed induces both intrinsic and extrinsic apoptosis through Ataxia telangiectasia mutated/p53-dependent and -independent signaling pathways. *Mol Carcinog* 2013; **52**: 183–194.
40. Yang TY, Chang GC, Chen KC, Hung HW, Hsu KH, Shyu GT et al. Sustained activation of ERK and Cdk2/cyclin-A signaling pathway by pemetrexed leading to S phase arrest and apoptosis in human non-small cell lung cancer A549 cells. *Eur J Pharmacol* 2011; **663**: 17–26.
41. Sanchez-Tillo E, Lazaro A, Torrejt R, Cuatrecasas M, Vaquerro EC, Castells A et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI/SNF chromatin-remodelling protein BRG1. *Oncogene* 2010; **29**: 3490–3500.
42. Dhillon AS, Tuohimäki E, FFA-1 as a driver of tumour heterogeneity: a nexus between oncogenes and embryonic signalling pathways in cancer. *Oncogene* 2013; **34**: 4421–4428.
43. Moadil M, Gu H, Yuen CY, Nizze M. Vinca alkaloids. *Int J Prev Med* 2013; **4**: 1231–1235.
44. Kerner H, Blieden JR, Ling V. Cell surface P-glycoprotein associated with multi-drug resistance in mammalian cell lines. *Science* 1983; **221**: 1285–1288.
45. McCroghan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. *Biochim Biophys Acta* 2008; **1785**: 95–133.
46. Zucali PA, Perrino M, Lorenzi F, Ceselli GL, De Vincenzo F, Simonelli M et al. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. *Lung Cancer* 2013; **84**: 265–270.
47. Chiu LY, Ku JL, Lee YJ, Yang TY, Tee YT, Shyu GT. L-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines. *Toxicol Lett* 2010; **192**: 466–470.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>

Supplementary Information accompanies this paper on the *Oncogene* website (<http://www.nature.com/onc>)

科技部補助專題研究計畫成果自評表

請就研究內容與原計畫相符程度、達成預期目標情況、研究成果之學術或應用價值（簡要敘述成果所代表之意義、價值、影響或進一步發展之可能性）、是否適合在學術期刊發表或申請專利、主要發現（簡要敘述成果是否具有政策應用參考價值及具影響公共利益之重大發現）或其他有關價值等，作一綜合評估。

1. 請就研究內容與原計畫相符程度、達成預期目標情況作一綜合評估

達成目標

說明：此年度計畫內容與上年度之計畫具有連續性，因此合併發表在期刊上。

2. 研究成果在學術期刊發表或申請專利等情形(請於其他欄註明專利及技轉之證號、合約、申請及洽談等詳細資訊)

論文： 已發表 Oncogene advance online publication, June 6, 2016;
doi:10.1038/onc.2016.195

專利： 已獲得 申請中 無

技轉： 無

3. 請依學術成就、技術創新、社會影響等方面，評估研究成果之學術或應用價值（以 500 字為限）。

我們以前曾經證明愛寧達會利用 ERK 的訊息路徑來引起肺癌細胞的凋亡，因此我們認為當經由 ERK 的訊息路徑無法引起肺癌細胞的凋亡而變成抗愛寧達藥物的肺癌細胞後，這個 ERK 的訊息路徑反而會增加肺癌細胞的轉移能力。同時，我們進一步使用另一類的化療藥敏畢瘤(vinblastine)以及敏克瘤(vincristine)來有效抑制愛寧達的抗藥性。我們的研究結果可以提供建議在面臨愛寧達的抗藥性時，使用長春花生物鹼類的化療藥物可能是有效緩解愛寧達抗藥性的方法，並且這方法不會因為 TP53 是否為野生型或突變型而有所影響。更重要的意義是長春花生物鹼類的化療藥物可以降低 ERK 蛋白激酶被磷酸化，所以會控制抗愛寧達藥物細胞的遷移和侵襲的能力。這一發現提供了新的認識來克服愛寧達抗藥性引起的肺癌轉移。

4. 主要發現

本研究具有政策應用參考價值： 否 是，建議提供機關_____

（勾選「是」者，請列舉建議可提供施政參考之業務主管機關）

本研究具影響公共利益之重大發現： 否 是

科技部補助專題研究計畫成果彙整表

計畫主持人：許國堂		計畫編號：MOST 104-2320-B-040-003-					
計畫名稱：研究長春鹼化療藥物對愛寧達之抗藥性肺癌細胞所引起的死亡機制							
		成果項目	量化	單位	質化 (說明：各成果項目請附佐證資料或細項說明，如期刊名稱、年份、卷期、起訖頁數、證號...等)		
國內	學術性論文	期刊論文		0	篇	請附期刊資訊。	
		研討會論文		1		第二十一屆台灣癌症聯合學術年會壁報論文 B1-020 2016-05-14 to 05-15	
		專書				本	請附專書資訊。
		專書論文				章	請附專書論文資訊。
		技術報告				篇	
		其他				篇	
	智慧財產權及成果	專利權	發明專利	申請中		件	請附佐證資料，如申請案號。
				已獲得			請附佐證資料，如獲證案號。
			新型/設計專利				
		商標權					
		營業秘密					
		積體電路電路布局權					
		著作權					
		品種權					
		其他					
	技術移轉	件數			件		
		收入			千元	1. 依「科技部科學技術研究發展成果歸屬及運用辦法」第2條規定，研發成果收入係指執行研究發展之單位因管理及運用研發成果所獲得之授權金、權利金、獎金、股權或其他權益。 2. 請註明合約金額。	
	國外	學術性論文	期刊論文		1	篇	Oncogene, advance online publication, June 6, 2016; doi:10.1038/onc.2016.195 (IF=7.932 ONCOLOGY R/C=15/213=7.04%).
			研討會論文				
			專書			本	請附專書資訊。

		專書論文			章	請附專書論文資訊。	
		技術報告			篇		
		其他			篇		
	智慧財產權 及成果	專利權	發明專利	申請中		件	請附佐證資料，如申請案號。
				已獲得			請附佐證資料，如獲證案號。
			新型/設計專利				
		商標權					
		營業秘密					
		積體電路電路布局權					
		著作權					
		品種權					
		其他					
	技術移轉	件數			件		
		收入			千元	1. 依「科技部科學技術研究發展成果歸屬及運用辦法」第2條規定，研發成果收入係指執行研究發展之單位因管理及運用研發成果所獲得之授權金、權利金、價金、股權或其他權益。 2. 請註明合約金額。	
參與計畫人力	本國籍	大專生		0	人次		
		碩士生		1			
		博士生		1			
		博士後研究員		1			
		專任助理		1			
	非本國籍	大專生		0			
		碩士生		0			
		博士生		0			
		博士後研究員		0			
		專任助理		0			
其他成果 (無法以量化表達之成果如辦理學術活動、獲得獎項、重要國際合作、研究成果國際影響力及其他協助產業技術發展之具體效益事項等，請以文字敘述填列。)							

科技部補助計畫衍生研發成果推廣資料表

日期:2016/08/31

科技部補助計畫	計畫名稱: 研究長春鹼化療藥物對愛寧達之抗藥性肺癌細胞所引起的死亡機制
	計畫主持人: 許國堂
	計畫編號: 104-2320-B-040-003- 學門領域: 藥理及毒理
無研發成果推廣資料	

104年度專題研究計畫成果彙整表

計畫主持人：許國堂		計畫編號：104-2320-B-040-003-				
計畫名稱：研究長春鹼化療藥物對愛寧達之抗藥性肺癌細胞所引起的死亡機制						
成果項目		量化	單位	質化 (說明：各成果項目請附佐證資料或細項說明，如期刊名稱、年份、卷期、起訖頁數、證號...等)		
國內	學術性論文	期刊論文	0	篇	第二十一屆台灣癌症聯合學術年會 2016-05-14 to 2016-05-15壁報編號B1-020(愛寧達的肺癌抗藥細胞經由ERK-ZEB1訊息路徑加強其上皮-間質的轉變可以被長春花生物鹼抑制)	
		研討會論文	1			
		專書	0			本
		專書論文	0			章
		技術報告	0			篇
		其他	0			篇
	智慧財產權及成果	專利權	發明專利	申請中	0	件
				已獲得	0	
			新型/設計專利	0		
		商標權	0			
		營業秘密	0			
		積體電路電路布局權	0			
		著作權	0			
		品種權	0			
		其他	0			
	技術移轉	件數	0	件		
		收入	0	千元		
	國外	學術性論文	期刊論文	1	篇	Oncogene advance online publication, June 6, 2016; doi:10.1038/onc.2016.195
			研討會論文	0		
			專書	0		本
專書論文			0	章		
技術報告			0	篇		
其他			0	篇		
智慧財產權及成果		專利權	發明專利	申請中	0	件
				已獲得	0	
			新型/設計專利	0		
		商標權	0			

		營業秘密	0		
		積體電路電路布局權	0		
		著作權	0		
		品種權	0		
		其他	0		
	技術移轉	件數	0	件	
		收入	0	千元	
參與計畫人力	本國籍	大專生	0	人次	
		碩士生	1		
		博士生	1		
		博士後研究員	1		
		專任助理	1		
	非本國籍	大專生	0		
		碩士生	0		
		博士生	0		
		博士後研究員	0		
		專任助理	0		
其他成果 (無法以量化表達之成果如辦理學術活動、獲得獎項、重要國際合作、研究成果國際影響力及其他協助產業技術發展之具體效益事項等，請以文字敘述填列。)			無		

科技部補助專題研究計畫成果自評表

請就研究內容與原計畫相符程度、達成預期目標情況、研究成果之學術或應用價值（簡要敘述成果所代表之意義、價值、影響或進一步發展之可能性）、是否適合在學術期刊發表或申請專利、主要發現（簡要敘述成果是否具有政策應用參考價值及具影響公共利益之重大發現）或其他有關價值等，作一綜合評估。

1. 請就研究內容與原計畫相符程度、達成預期目標情況作一綜合評估

達成目標

未達成目標（請說明，以100字為限）

實驗失敗

因故實驗中斷

其他原因

說明：

2. 研究成果在學術期刊發表或申請專利等情形（請於其他欄註明專利及技轉之證號、合約、申請及洽談等詳細資訊）

論文： 已發表 未發表之文稿 撰寫中 無

專利： 已獲得 申請中 無

技轉： 已技轉 洽談中 無

其他：（以200字為限）

Oncogene advance online publication, June 6, 2016;

doi:10.1038/onc.2016.195

3. 請依學術成就、技術創新、社會影響等方面，評估研究成果之學術或應用價值（簡要敘述成果所代表之意義、價值、影響或進一步發展之可能性，以500字為限）

我們以前曾經證明愛寧達會利用ERK的訊息路徑來引起肺癌細胞的凋亡，因此我們認為當經由ERK的訊息路徑無法引起肺癌細胞的凋亡而變成抗愛寧達藥物的肺癌細胞後，這個ERK的訊息路徑反而會增加肺癌細胞的轉移能力。同時，我們進一步使用另一類的化療藥敏畢瘤(vinblastine)以及敏克瘤(vincristine)來有效抑制愛寧達的抗藥性。我們的研究結果可以提供建議在面臨愛寧達的抗藥性時，使用長春花生物鹼類的化療藥物可能是有效緩解愛寧達抗藥性的方法，並且這方法不會因為TP53是否為野生型或突變型而有所影響。更重要的意義是長春花生物鹼類的化療藥物可以降低ERK蛋白激酶被磷酸化，所以會控制抗愛寧達藥物細胞的遷移和侵襲的能力。

4. 主要發現

本研究具有政策應用參考價值： 否 是，建議提供機關

（勾選「是」者，請列舉建議可提供施政參考之業務主管機關）

本研究具影響公共利益之重大發現： 否 是

說明：（以150字為限）

長春花生物鹼類的化療藥物可以降低ERK蛋白激酶被磷酸化，所以會控制抗愛寧達藥物細胞的遷移和侵襲的能力。這一發現提供了新的認識來克服愛寧達抗

藥性引起的肺癌轉移。